Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06582771 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Sotorasib in People With Non-Small Cell Lung Cancer

StatusRecruiting
PhasePhase 2
Started2024-08-30
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Aug 2026 → Aug 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Amendment history

2026-09-10
Study Status v5
Primary completion pushed: 2026-08 → 2027-08
Completion pushed: 2026-08 → 2027-08
2026-03-23
2 amendments v3-v4
2 re-verifications since 2026-02-04, no change to tracked fields
2025-10-22
Study Identification, Study Status, Oversight, Eligibility, Contacts/Locations v2
Eligibility criteria-1 characters
[...] s (KPS) ≥ 70% Age ≥ 18 Adequate organ function Hemoglobin ≥ 109^9 g/dL Platelets ≥ 75 x 10^9/L Absolute neutrophil count (A [...]
Study sitesdetails revised at 1 of 7 sites
Study titlerevised
A Study of Sotorasib in People withWith Non-Small Cell Lung Cancer
2024-11-11
Study Identification, Study Status, Oversight, Contacts/Locations v1
Study sitesdetails revised at 1 of 7 sites
Study titlerevised
A Study of Sotorasib in People Withwith Non-Small Cell Lung Cancer
2024-08-30
Original filing
The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)
Trial Details
NCT Number NCT06582771
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Non Small Lung Cancer
Enrollment 39 participants
Start Date 2024-08-30
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-11